Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome.
UNLABELLED: Neuroleptic Malignant Syndrome (NMS) rarely results from atypical antipsychotic therapy. To date, no information is available on the incidence of NMS with aripiprazole, a newer neuroleptic. OBJECTIVE: To examine the results of a trial of aripiprazole administered to a 13-year-old Mexican-American girl during the course of NMS. METHODS: Vital signs and laboratory values obtained before and during the aripiprazole trial were compared. RESULTS: Aripiprazole administration resulted in a mild increase in tachycardia and brief worsening of serum creatinine kinase level, but did not significantly affect temperature, respiratory rate, or blood pressure. CONCLUSIONS: In this adolescent with NMS, aripiprazole treatment was associated with a mild worsening of symptoms.
Duke Scholars
Published In
DOI
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- United States
- Quinolones
- Public Health
- Piperazines
- Neuroleptic Malignant Syndrome
- Mexican Americans
- Humans
- Female
- Aripiprazole
- Antipsychotic Agents
Citation
Published In
DOI
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- United States
- Quinolones
- Public Health
- Piperazines
- Neuroleptic Malignant Syndrome
- Mexican Americans
- Humans
- Female
- Aripiprazole
- Antipsychotic Agents